Learn more

MOLECULAR ENGINES LAB

Overview
  • Total Patents
    37
About

MOLECULAR ENGINES LAB has a total of 37 patent applications. Its first patent ever was published in 1999. It filed its patents most often in WIPO (World Intellectual Property Organization), Canada and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and agriculture are MAINE MEDICAL CT RES INST, HOSHINO TOMOAKI and AUSTRALIAN POULTRY CRC PTY LTD.

Patent filings in countries

World map showing MOLECULAR ENGINES LABs patent filings in countries
# Country Total Patents
#1 WIPO (World Intellectual Property Organization) 19
#2 Canada 6
#3 EPO (European Patent Office) 6
#4 France 4
#5 United States 2

Patent filings per year

Chart showing MOLECULAR ENGINES LABs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Telerman Adam 36
#2 Amson Robert 36
#3 Tuijnder Marius 19
#4 Susini Laurent 11
#5 Passer Brent 6
#6 Tuijnder Marcel 5
#7 Roperch Jean-Pierre 3
#8 Lassalle Jean-Michel 3
#9 Oren Moshe 2
#10 Schneider Boris 1

Latest patents

Publication Filing date Title
WO2004065572A2 Proteic binding partners of tctp and methods of modulating tumor reversion or cell apoptosis
WO03097835A2 Pharmaceutical compositions for the treatment of cancer
WO03087122A2 Sequences involved in the phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses, and the use of the same as medicaments
WO03087154A2 Sequences involved in the phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses, and the use of the same as medicaments
WO03087372A2 Growth factor derived from hepatome and the use of the same
WO03087153A1 Mouse kruppel-type zinc finger protein knox-25 and the use of thereof
WO03025176A2 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
WO03025175A2 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
WO03025177A2 Sequences involved in phenomena of tumour suppression, tumour reversion, adoptosis and/or resistance to viruses and the use thereof as medicaments
WO03040369A2 Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines
WO03004526A2 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines
FR2822475A1 Sequences involved in the phenomena of tumor depression, tumor reversion, apoptosis and / or virus resistance and their use as medicaments
WO02059256A2 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
CA2432214A1 Gene involved in apoptosis regulation
WO02052274A2 Screening method based on tsap6 binding partners
CA2432683A1 Screening method based on siah-numb interaction
FR2825279A1 Useful medicine in the treatment of cancer
FR2825371A1 REVERTANT CELLS FROM A BREAST TUMOR
FR2820757A1 Sequences involved in the phenomena of tumor depression, tumor reversion, apoptosis and / or virus resistance and their use as medicaments